|
1
|
CARLO‐STELLA C, Linhares Y, Gandhi MD, Chung M, Adamis H, Ungar D, Hamadani M. PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE PLUS RITUXIMAB VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA – LOTIS‐5. Hematol Oncol 2021. [DOI: 10.1002/hon.163_2880] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- C. CARLO‐STELLA
- Humanitas Clinical and Research Center ‐ IRCCS and Humanitas University Department of Oncology and Hematology Rozzano Milan Italy
| | - Y. Linhares
- Miami Cancer Institute Baptist Health Medical Oncology Miami USA
| | - M. D. Gandhi
- Virginia Cancer Specialists, Medical Oncology Gainesville USA
| | - M. Chung
- The Oncology Institute of Hope and Innovation Hematology/Oncology Downey USA
| | - H. Adamis
- ADC Therapeutics SA Clinical Development Epalinges Switzerland
| | - D. Ungar
- ADC Therapeutics America, Inc Clinical Development Murray Hill USA
| | - M. Hamadani
- Medical College of Wisconsin Division of Hematology and Oncology Milwaukee USA
| |
Collapse
|